top of page
  • syun573

Our store-front at

EMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front at Scienist.Com for expedited study quoting and contracting.

E-slice enables efficacy, target validation, and MOA studies, including chemo, targeted, immune, virotherapy, cell-based and combinations while maintaining the native TME cell-cell and cell-matrix interactions unique to each patient’s tumor. Results are availalable in a clinically-actionable time frame of 4-8 days with tissue viability out to 28+ days in many cases.

Contact us if there is interest in a detailed discussion around how E-slice can be used to enhance both preclinical drug discovery and development efforts and clinical diagnosis. #cancerresearch #immunotherapy #drugdiscovery #scRNAseq #clinicaltrials #oncology #3dculture #TME #cancerdrugs #ESlice

Recent Posts

See All


San Francisco, CA, Jan 8, 2023– EMPIRI today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view EMPIRI’s presentation live, and also access a recorded

Top 10 Most Promising Company, Once Again

At the 11th annual Texas Life Science Forum, held on November 8, 2022, EMPIRI Inc. was once again recognized as one of the Rice Alliance Most Promising Life Science Companies for our E-Slice technolog


bottom of page